{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-24-000034","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.087447+00:00","generated_at":"2026-05-29T11:24:34.019901+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novocure's PANOVA-3 Phase 3 trial meets primary endpoint in pancreatic cancer; plans regulatory filings","bullets":["PANOVA-3 met primary endpoint: mOS 16.20 months (TTFields) vs 14.16 months (control), HR=0.819, p=0.039 (N=571).","Survival rate benefit increased over time: 13% improvement at 12 months, 33% improvement at 24 months.","TTFields therapy was well-tolerated; safety consistent with prior studies.","Novocure plans regulatory filings in U.S., EU, Japan, and other key markets based on PANOVA-3.","This is Novocure's third positive Phase 3 trial in two years; full results at upcoming congress."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-24-000034","json":"https://secwatch.observer/filing/0001645113-24-000034.json","markdown":"https://secwatch.observer/filing/0001645113-24-000034.md","text":"https://secwatch.observer/filing/0001645113-24-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000034/0001645113-24-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511324000034/nvcr-20241202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:24:34.019901+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}